Apellis generated 199913000 in total revenue in Q4 2025, primarily from SYFOVRE and EMPAVELI product sales, and reported a net loss of 58951000 as operating expenses exceeded gross profit.

Apellis Pharmaceuticals reported total revenue of $178.5 million for Q2 2025, driven by strong U.S. net product sales of SYFOVRE ($150.6 million) and EMPAVELI ($20.8 million). The company also announced the FDA approval of EMPAVELI for C3G and primary IC-MPGN, and a capped royalty purchase agreement with Sobi for up to $300 million, which is expected to help fund the business to profitability.

Apellis Pharmaceuticals, Inc. experienced a decrease in total revenue to $166,797 thousand in Q1 2025 from $172,325 thousand in Q1 2024, primarily due to a decline in product revenue from SYFOVRE and EMPAVELI. The company's net loss increased to $92,225 thousand from $66,423 thousand in the prior year, driven by higher cost of sales and increased interest expense.

Apellis Pharmaceuticals delivered a solid Q4 2024 performance with $212.53 million in revenue, a 45.2% year-over-year increase. The company continued to grow sales of its flagship products, SYFOVRE and EMPAVELI. Despite revenue growth, the company posted a net loss of $36.35 million, improving from a loss of $88.58 million in Q4 2023.

Apellis Pharmaceuticals reported a total revenue of $146.4 million for Q4 2023, driven by $114.3 million from SYFOVRE and $24.4 million from EMPAVELI. The company's net loss was $88.5 million for the quarter. The company had $351.2 million in cash and cash equivalents as of December 31, 2023.

Apellis Pharmaceuticals reported a total revenue of $95.0 million for Q2 2023, driven by $67.3 million from SYFOVRE and $22.3 million from EMPAVELI. The company's cash and cash equivalents stood at $616.3 million as of June 30, 2023. A comprehensive investigation found no indication of drug product or manufacturing issues contributing to the rare events of retinal vasculitis with SYFOVRE.